12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NKTR-192: Phase Ia data

A single ascending-dose Phase Ia trial in healthy volunteers showed that NKTR-192 achieved a short-acting pharmacokinetic profile, which Nektar said is ideal for the treatment of...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >